The Immunoglobulin G4-Related Disease (IgG4-RD) drugs in development market research report provides comprehensive information on the therapeutics under development for Immunoglobulin G4-Related Disease (IgG4-RD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Immunoglobulin G4-Related Disease (IgG4-RD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Immunoglobulin G4-Related Disease (IgG4-RD) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Immunoglobulin G4-Related Disease (IgG4-RD) by eight companies/universities/institutes. The top development phase for Immunoglobulin G4-Related Disease (IgG4-RD) is phase ii with three drugs in that stage. The Immunoglobulin G4-Related Disease (IgG4-RD) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Immunoglobulin G4-Related Disease (IgG4-RD) pipeline products market are: Amgen, Mitsubishi Tanabe Pharma and Principia Biopharma.
The key targets in the Immunoglobulin G4-Related Disease (IgG4-RD) pipeline products market include B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), and Cells Expressing SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like Receptor Activating Cytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7).
The key mechanisms of action in the Immunoglobulin G4-Related Disease (IgG4-RD) pipeline product include B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) Inhibitor with two drugs in Phase III. The Immunoglobulin G4-Related Disease (IgG4-RD) pipeline products include five routes of administration with the top ROA being Subcutaneous and three key molecule types in the Immunoglobulin G4-Related Disease (IgG4-RD) pipeline products market including Monoclonal Antibody, and Fusion Protein.
Immunoglobulin G4-Related Disease (IgG4-RD) overview
Immunoglobulin-G4 related disease is an immune-mediated condition that can affect multiple organ systems. It is a fibro-inflammatory condition with tumefactive lesions of unknown etiology and characteristic histopathological features. This is also known as IgG4-related systemic disease, hyper-IgG4 disease, IgG4-related autoimmune disease, IgG4-associated disease, IgG4-related sclerosing disease, and IgG4-syndrome.
For a complete picture of Immunoglobulin G4-Related Disease (IgG4-RD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
